Pyxis Oncology, INC 8-K filings

Pyxis Oncology reported Q2 2026 results, announcing a private placement financing of up to $114 million, with approximately $50 million upfront, extending its cash runway into Q2 2027 and providing updates on its MICVO clinical program.

Pyxis Oncology announced a $50 million private placement financing to advance its lead drug candidate, MICVO, through key clinical milestones.

Pyxis Oncology, Inc. announced the results of its Annual Meeting of Stockholders held on June 15, 2026, including the election of directors and ratification of its independent auditor.

Pyxis Oncology announced its first quarter 2026 financial results, highlighting progress in its micvotabart pelidotin (MICVO) clinical development program and providing an updated cash runway into Q4 2026.

Pyxis Oncology amends prior 8-K to detail CEO Lara Sullivan's separation agreement, including continued salary, health benefits, and accelerated equity vesting.

Pyxis Oncology announced full year 2025 financial results and positive clinical updates for its lead cancer therapeutic, MICVO, in head and neck cancer.

Pyxis Oncology announces the departure of CEO Dr. Lara Sullivan and the appointment of current director Tom Civik as Interim CEO to ensure strategic continuity.

Pyxis Oncology announced positive preliminary Phase 1 data for its lead candidate, MICVO, in recurrent/metastatic head and neck squamous cell carcinoma, both as monotherapy and in combination with KEYTRUDA.

Pyxis Oncology announced its third-quarter 2025 financial results and provided a corporate update, with preliminary clinical data for its lead candidate MICVO in R/M HNSCC expected in Q4 2025.

Pyxis Oncology announced its second quarter 2025 financial results and provided updates on its lead antibody-drug conjugate (ADC) therapeutic, micvotabart pelidotin (MICVO), including clinical trial progress and a milestone payment.

Pyxis Oncology, Inc. announced revisions to patient enrollment for its Phase 1 clinical trial of micvotabart pelidotin (MICVO), reflecting the maximum number of patients allowed per protocol.

Pyxis Oncology, Inc. announced the retirement of its Chief Financial Officer and Chief Operating Officer, Pamela Connealy, and the appointment of Jitendra Wadhane as Principal Financial Officer, effective July 1, 2025.

Pyxis Oncology, Inc. announced the successful election of three Class I directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Pyxis Oncology reported its Q1 2025 financial results and provided a business update, highlighting progress with its lead candidate, micvotabart pelidotin (MICVO), and upcoming data milestones.

Pyxis Oncology highlights encouraging early clinical data for its ADC candidate, micvotabart pelidotin, and outlines its strategic focus on head and neck squamous cell carcinoma (HNSCC) with multiple data catalysts expected in 2025 and 2026.

Pyxis Oncology reports positive preliminary data from its Phase 1 trial of micvotabart pelidotin (MICVO) in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC), receives FDA Fast Track Designation, and streamlines operations to focus on MICVO clinical program.

Pyxis Oncology's PYX-201, an antibody-drug conjugate, has been granted Fast Track Designation by the FDA for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma.

Pyxis Oncology announces the initiation of a Phase 1/2 combination trial of PYX-201 with Merck's Keytruda and the expansion of monotherapy cohorts in its ongoing Phase 1 PYX-201-101 study.

Pyxis Oncology is focusing its resources on advancing its lead clinical program, PYX-201, an antibody-drug conjugate, after seeing positive preliminary results in a Phase 1 trial.

Pyxis Oncology reports promising initial results from its Phase 1 trial of PYX-201, showing a 50% objective response rate in head and neck cancer patients and a 26% overall response rate across six solid tumor types.

Pyxis Oncology announced its third quarter 2024 financial results, highlighted by a cash runway into the second half of 2026 and provided updates on its clinical programs for PYX-201 and PYX-106.

Pyxis Oncology stockholders approved an amendment to the 2021 Equity and Incentive Plan, increasing the available shares by 5,500,000, at a special meeting held on October 23, 2024.

Pyxis Oncology announced its second quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical programs and a cash runway into the second half of 2026.

Pyxis Oncology held its annual meeting on June 11, 2024, electing directors and ratifying its independent auditor.

Pyxis Oncology has appointed Michael A. Metzger, a seasoned biopharmaceutical executive, to its Board of Directors, effective June 10, 2024.

Pyxis Oncology announced its first quarter 2024 financial results, provided updates on its clinical programs, and appointed a new Chief Business Officer.

Pyxis Oncology has released updated unaudited pro forma financial information to reflect the acquisition of Apexigen, showing combined results as if the merger occurred at the beginning of 2023.

Pyxis Oncology has sold its royalty rights for Beovu and another asset to Novartis for $8 million, providing non-dilutive funding for its lead ADC asset.

Pyxis Oncology announced its full year 2023 financial results and provided a corporate update, highlighting progress in its clinical trials and a recent $50 million private placement.

Pyxis Oncology has appointed Santhosh Palani, Ph.D., CFA, to its Board of Directors, effective March 12, 2024.